Safety of 30 min infusion of durvalumab (D) in combination with gemcitabine (G)-based chemotherapy in first-line treatment (tx) of advanced biliary tract cancer (aBTC): TOURMALINE early results

Key Points

• Safety data indicates that administering durvalumab with gemcitabine through a 30 min infusion is feasible for treatment.
• Preliminary results demonstrate effective support for chemotherapy in patients with advanced biliary tract cancer, potentially streamlining care.
• Conducted as a Phase 3b single-arm study, the focus was on the safety profile of the new infusion regimen.
• These early findings highlight the need for further research to assess long-term outcomes and overall effectiveness.

Abstract